权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of IM Formulation of (2S,3S)-SPD for Nerve Agent Seizures

用于神经毒剂癫痫发作的 (2S,3S)-SPD 肌内注射制剂的开发

基本信息

批准号：
10237326
负责人：
Meir Bialer
金额：
$ 65.98万
依托单位：
UNIVERSITY OF CALIFORNIA AT DAVIS
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-08-15 至 2023-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10237326
关键词：
Advanced Development Amides Anatomy Animal Model Animals Autopsy Back Behavioral Benzodiazepines Brain Cardiotoxicity Chemicals Child Cholinesterase Inhibitors Chromosome abnormality Cognitive Data Data Element Data Set Development Diazepam Domestic Pig Dose Drug Kinetics Electrographic Status Epilepticus Environment Epilepsy Evaluation Exhibits Exposure to Female Formulation Free Will Goals Human In Vitro Individual Intramuscular Laboratories Laboratory Study Lithium Measures Medical Research Medical emergency Midazolam Modeling Mus Neurological outcome Organic solvent product Pediatrics Pharmaceutical Preparations Physiological Pilocarpine Plasma Population Process Product Approvals Production Rattus Research Research Institute Resistance Rodent Route Safety Sampling Sarin Scheme Seizures Soman Special Population Standardization Status Epilepticus Stereoisomer Teratogens Test Result Testing Therapeutic Time Toxicology Toxin United States Dept. of Health and Human Services United States National Institutes of Health Valproic Acid animal rule aqueous chemical threat design efficacy study enantiomer gamma-Aminobutyric Acid immature animal improved in vitro testing in vivo interest intraperitoneal male mass casualty medical countermeasure nerve agent neuroprotection programs safety study safety testing sex stability testing standard of care stem cells tetramethylenedisulfotetramine

项目摘要

Project Summary/Abstract This project seeks to advance the development of (2S,3S)-sec-butylpropylacetamide [(2S,3S)-SPD] for the treatment of chemical threat agent seizures. A priority of the NIH CounterACT Program is the development of medical countermeasures to treat seizures induced by anticholinesterase nerve agents such as soman and sarin or GABA-inhibiting agents such as tetramethylenedisulfotetramine (TETS). Benzodiazepines, the current standard-of-care therapies, fail to stop seizures induced by such agents when there is more than a brief delay between onset of seizures and administration of the treatment agent. In rodents, (2S,3S)-SPD is a broad- spectrum antiseizure agent that effectively stops benzodiazepine-resistant behavioral and electrographic status epilepticus in the lithium-pilocarpine model. Moreover, studies conducted at the U.S. Army Medical Research Institute of Chemical Defense indicate that (2S,3S)-SPD rapidly stops soman-induced benzodiazepine- resistant SE in rats at delayed time points, an effect not shared by benzodiazepines or other antiseizure drugs. Therefore, (2S,3S)-SPD has promise to provide a major improvement to the current standard-of-care for the treatment of nerve agent seizures. The objective of the proposed research is to generate the data required to advance the development of an intramuscular formulation (2S,3S)-SPD so that it is available as a medical countermeasure for nerve agent seizures in the setting of a civilian exposure. A scalable synthesis route for (2S,3S)-SPD will be developed. The API will be formulated in a solution designed for intramuscular administration, a “mass-casualty-friendly” route of delivery that offers fast onset of action. Initial toxicology and safety studies will be conducted in animals, including studies to assess safety in both males and females and in special populations such as children. Additional proof-of-concept and dose-ranging studies in relevant animal models will be conducted, including in a model of TETS-induced status epilepticus. The proposed research will assess the potential of (2S,3S)-SPD as an improved medical countermeasure to treat seizures induced by diverse chemical threat agents. On completion of the project, a comprehensive set of data will be available to advance the development of (2S,3S)-SPD as an improved treatment for chemical threat agent seizures.

项目总结/摘要本项目旨在推进（2S，3S）-仲丁基丙基乙酰胺[（2S，3S）-SPD]的开发，治疗化学威胁剂癫痫发作。NIH CounterACT计划的一个优先事项是开发治疗由抗胆碱酯酶神经剂如梭曼和沙林或GABA抑制剂，如四亚甲基二磺基四胺（TETS）。苯二氮卓类，目前标准护理疗法，当存在超过短暂的延迟时，不能阻止由这些药物诱导的癫痫发作在癫痫发作和治疗剂给药之间。在啮齿类动物中，（2S，3S）-SPD是一种广泛的- 有效阻止苯二氮卓类耐药性行为和电描记状态的光谱抗癫痫药锂-匹罗卡品模型中的癫痫。此外，美国陆军医学研究所进行的研究表明，化学防御研究所的研究表明，（2S，3S）-SPD可迅速阻止梭曼诱导的苯二氮卓类药物- 在延迟的时间点，大鼠对SE耐药，苯二氮卓类药物或其他抗癫痫药物不具有这种作用。因此，（2S，3S）-SPD承诺对当前的护理标准进行重大改进神经毒剂癫痫的治疗拟议研究的目的是生成所需的数据，推进肌内制剂（2S，3S）-SPD的开发，使其可用作医疗在平民暴露的情况下缴获神经毒剂的对策。可扩展的合成路线， (2S，3S）-SPD将被开发。API将配制成用于肌内给药的溶液。这是一种“对大规模伤亡友好”的交付途径，提供了快速的行动开始。初步毒理学和将在动物中进行安全性研究，包括评估雄性和雌性动物安全性的研究，特殊人群，如儿童。相关研究中的其他概念验证和剂量范围研究将进行动物模型，包括TETS诱导的癫痫持续状态模型。拟议研究将评估（2S，3S）-SPD作为治疗癫痫发作的改进医疗对策的潜力由多种化学威胁剂引起。项目完成后，将提供一套全面的数据，可用于推进（2S，3S）-SPD作为化学威胁剂的改进处理的开发癫痫发作